Testicular dysfunctions in patients after cytostatic treatment of non-seminomatous testis tumours.
In recent two years 28 patients were treated by combined cytostatic therapy for non-seminomatous testis tumour. Eleven months on the average since finishing chemotherapy they underwent andrological examination aimed at the changes of testicular function. Influence of cytostatics--bleomycin, cisplatinum and vinblastine on spermiogenesis of patient, on contralateral testis unaffected by tumour and on potency (data on erection, orgasm, volume of ejaculate and coitus frequency) was observed. 20% of patients had diminished contralateral testis. Decrease of ejaculate volume was stated by 64% of patients. Spermiogenesis damage was established in all patients (86% of patients had azoospermia and 14% had difficult oligoasthenospermia). One of the possible solutions of this negative effect on male fertility is represented by cryopreservation of semen before introduction of chemotherapy.
Ondrus
D
D
Vrabec
J
J
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D006801:Humans; D008297:Male; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced*; D013091:Spermatogenesis / Q000187:drug effects*; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin